Andere Sprachen Natera, Inc.

Aktien

A14VPJ

US6323071042

NTRA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
91,5 ^USD	+0,51 %		+1,30 %	+46,07 %

18.04.	Natera-Insider verkauft Aktien im Wert von $7.265.651, laut einer aktuellen SEC-Einreichung	MT
18.04.	Natera-Insider verkauft Aktien im Wert von $634.797, laut einer aktuellen SEC-Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications	22.04.
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	18.04.
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	18.04.
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation	11.04.
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	11.04.
Natera Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients	09.04.
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients	08.04.
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	08.04.
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	08.04.
North American Morning Briefing : Inflation Data, -2-	08.04.
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	05.04.
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing	05.04.
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	05.04.
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103, A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	02.04.
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	01.04.
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	01.04.
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer	18.03.
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer	18.03.
Natera, Inc. - New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease	15.03.
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease	14.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Natera, Inc.

Aktien

A14VPJ

US6323071042

NTRA

Andere Sprachen

Filter